Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients
- PMID: 2488207
Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients
Abstract
The single dose pharmacokinetics of recombinant human erythropoietin (r-HuEPO) were compared in six continuous ambulatory peritoneal dialysis (CAPD) patients after intravenous (i.v.), subcutaneous (s.c.), and intraperitoneal (i.p.) administration of 300 U/kg. Intravenous administration gave results close to those obtained in hemodialysis patients, with a half-life of 11.2 h and a volume of distribution of 5.0% of body weight. After subcutaneous administration, the serum concentration rose slowly to plateau between 24 and 36 h, the area under the serum concentration vs. time curve from 6 to 72 h being 18.2% of that after intravenous administration. After intraperitoneal administration, the serum concentration was even lower, the area under the curve from 0 to 24 h was between 2.5 and 3.6% of that after intravenous administration, and 80% of the administered dose was recovered in the first peritoneal effluent after a 4-h dwell time.
Comment in
-
Accuracy of erythropoietin determination in dialysate of CAPD patients.Perit Dial Int. 1990;10(2):184-5. Perit Dial Int. 1990. PMID: 2085612 No abstract available.
Similar articles
-
Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis.Eur J Pediatr. 1994 Nov;153(11):850-4. doi: 10.1007/BF01972896. Eur J Pediatr. 1994. PMID: 7843202 Clinical Trial.
-
Effect of erythropoietin in continuous ambulatory peritoneal dialysis patients: comparison between intravenous and intraperitoneal administration.Perit Dial Int. 1992;12(4):373-7. Perit Dial Int. 1992. PMID: 1420496
-
Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.Clin Nephrol. 1990 Jan;33(1):47-51. Clin Nephrol. 1990. PMID: 2302870
-
Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous.Acta Haematol. 1992;87 Suppl 1:16-9. doi: 10.1159/000204783. Acta Haematol. 1992. PMID: 1574961 Review.
-
Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation.Am J Kidney Dis. 1989 Sep;14(3):163-9. doi: 10.1016/s0272-6386(89)80066-6. Am J Kidney Dis. 1989. PMID: 2672796 Review. No abstract available.
Cited by
-
Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis.Eur J Pediatr. 1994 Nov;153(11):850-4. doi: 10.1007/BF01972896. Eur J Pediatr. 1994. PMID: 7843202 Clinical Trial.
-
Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure.Pediatr Nephrol. 1993 Feb;7(1):61-4. doi: 10.1007/BF00861571. Pediatr Nephrol. 1993. PMID: 8439481
-
Intraperitoneal production of erythropoietin with continuous ambulatory peritoneal dialysis.Pediatr Nephrol. 1993 Jun;7(3):281-3. doi: 10.1007/BF00853222. Pediatr Nephrol. 1993. PMID: 8518099
-
Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).Clin Pharmacokinet. 1991 Feb;20(2):99-113. doi: 10.2165/00003088-199120020-00002. Clin Pharmacokinet. 1991. PMID: 2029809 Review.
-
Pharmacokinetics of newer drugs in patients with renal impairment (Part I).Clin Pharmacokinet. 1991 Apr;20(4):293-310. doi: 10.2165/00003088-199120040-00004. Clin Pharmacokinet. 1991. PMID: 2036748 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical